Turk J Med Sci. 2014;44(2):283-7.
The hepatitis B virus (HBV) is an important healthcare problem. Chronic hepatitis B infection may present with a wide range of manifestations from inactive carrier state to cirrhosis and hepatocellular cancer. Therefore, treatment is very important in chronic hepatitis B. In this study, the treatment results of 199 chronic hepatitis B patients taking entecavir 0.5 mg/day for 48 weeks were evaluated.
This study retrospectively evaluated data of 199 treatment-naive chronic hepatitis B patients who were treated with entecavir.
Of the 199 treatment-naive chronic hepatitis B patients, 141 (70.9%) were males and 58 (29.1%) were females, and mean age of the whole group was 37.5 ± 12.1 years. HBeAg was positive in 91 (45.7%) and antiHBe was positive in 108 (54.3%) patients. Mean HBV DNA value was 666,449,365.5 ± 2,759,013,996.9 IU/mL, mean ALT value was 112.1 ± 95.7 U/L, and mean AST value was 95.3 _ 71.2 U/L. At week 24 of the treatment, HBV DNA levels were below 50 IU/mL in 56% of the HBeAg-positive and 76% of the HBeAg-negative patients. At week 48 of the treatment, HBV DNA levels were below 50 IU/mL in 79% of the HBeAg-positive and 87% of the HBeAg- negative patients. At week 24, ALT had normalized in 72% of the HBeAg-positive and 79% of the HBeAg-negative patients. At week 48, ALT had normalized in 89% of the HBeAg-positive and 88% of the HBeAg-negative patients. AntiHBe seroconversion was seen in 2 of 91 patients (2.2%), but the loss of HBsAg was never observed.
The 48-week entecavir treatment at a dose of 0.5 mg/day was shown to be effective both for HBeAg-positive and negative patients.
乙型肝炎病毒（HBV）是一个重要的医疗保健问题。慢性乙型肝炎感染可能表现为从非活动性携带者状态到肝硬化和肝细胞癌等多种表现。因此，治疗在慢性乙型肝炎中非常重要。本研究评估了 199 例接受恩替卡韦 0.5mg/天治疗 48 周的慢性乙型肝炎患者的治疗结果。
本研究回顾性评估了 199 例接受恩替卡韦治疗的初治慢性乙型肝炎患者的数据。
199 例初治慢性乙型肝炎患者中，男性 141 例（70.9%），女性 58 例（29.1%），全组平均年龄为 37.5±12.1 岁。HBeAg 阳性 91 例（45.7%），抗 HBe 阳性 108 例（54.3%）。平均 HBV DNA 值为 666,449,365.5±2,759,013,996.9IU/ml，平均 ALT 值为 112.1±95.7U/L，AST 值为 95.3_71.2U/L。治疗 24 周时，HBeAg 阳性患者中有 56%和 HBeAg 阴性患者中有 76%的 HBV DNA 水平低于 50IU/ml。治疗 48 周时，HBeAg 阳性患者中有 79%和 HBeAg 阴性患者中有 87%的 HBV DNA 水平低于 50IU/ml。治疗 24 周时，HBeAg 阳性患者中有 72%和 HBeAg 阴性患者中有 79%的 ALT 正常。治疗 48 周时，HBeAg 阳性患者中有 89%和 HBeAg 阴性患者中有 88%的 ALT 正常。91 例 HBeAg 阳性患者中有 2 例（2.2%）发生抗 HBe 血清学转换，但从未观察到 HBsAg 丢失。
0.5mg/天恩替卡韦治疗 48 周对 HBeAg 阳性和阴性患者均有效。
